Director, Scientific Affairs
Celerion
Dr. Sabina Paglialunga is the Director, Scientific Affairs at Celerion where she provides scientific support for early clinical studies, client consultation and subject matter expertise for metabolic disease drug development programs. She also contributes to Celerion’s reputation for strong science through publications, presentations and webinars. Her areas of expertise include the obesity, type 2 diabetes and nonalcoholic steatohepatitis (NASH) indications. Dr. Paglialunga joined Celerion in April 2015.
Her in-depth knowledge of metabolic pathologies was gained during 10 years of research experience. Dr. Paglialunga received her PhD from McGill Univ, Canada in the Dept of Biochemistry. Her training also includes three Postdoctoral Fellowships (Maastricht Univ, the Netherlands; Univ of Guelph and Univ of Waterloo, Canada), where her research focused on lipid metabolism and glucose homeostasis with specialization in bioenergetics and oxidative stress in skeletal muscle, adipose tissue and the pancreas. Dr. Paglialunga has also contributed to more than 40 publications in top tier diabetes and physiology journals.